Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Sales and Divestitures (2016 - 2022)

Arrowhead Pharmaceuticals' Gains from Sales and Divestitures history spans 8 years, with the latest figure at $931063.0 for Q1 2022.

  • For Q1 2022, Gains from Sales and Divestitures rose 13.05% year-over-year to $931063.0; the TTM value through Mar 2022 reached $931063.0, up 13.05%, while the annual FY2021 figure was $899025.0, 22.42% down from the prior year.
  • Gains from Sales and Divestitures reached $931063.0 in Q1 2022 per ARWR's latest filing, up from $263700.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.2 million in Q1 2019 to a low of $263700.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $1.1 million, with a median of $955404.0 recorded in 2020.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 6489.59% in 2018, then tumbled 56.52% in 2020.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $658959.0 in 2018, then dropped by 19.06% to $533333.0 in 2019, then plummeted by 47.44% to $280325.0 in 2020, then dropped by 5.93% to $263700.0 in 2021, then surged by 253.08% to $931063.0 in 2022.
  • Per Business Quant, the three most recent readings for ARWR's Gains from Sales and Divestitures are $931063.0 (Q1 2022), $263700.0 (Q4 2021), and $899025.0 (Q3 2021).